Medicinal Cannabis Biotech Company Medigrowth is expanding into pain relief and health solutions for pets — and seeking investors
- Replies 0
In the heart of Melbourne, a groundbreaking initiative is taking shape that promises to revolutionise the way we care for our furry friends. Medigrowth*, a biotech company specialising in medicinal cannabis, is expanding its horizons with a new division called Kindred*, dedicated to enhancing veterinary care through the power of plant-based medicine.
This caught our attention not just because of the opportunities it presents for pet owners but also from an investment perspective—more on that shortly.
Pets are more than just animals; they're beloved companions that bring joy, comfort, and a sense of purpose. As our pets age alongside us, they, too, face health challenges, from anxiety to chronic pain and arthritis. It's heart-wrenching to see them in discomfort, and traditional treatments can sometimes fall short. That's where Kindred steps in*, offering a new hope for pet health and wellness.
Kindred's mission is rooted in the belief that pets deserve the same level of care and attention as their human counterparts. Leveraging the success of Medigrowth's human medicinal cannabis products, Kindred is introducing a comprehensive range of veterinary products, including high-quality supplements and prescription-based medicinal cannabis treatments* for a tailored approach to address various pet health issues.
Recent CBD medication trials in dogs have shown promising results, with 83% of participating canines exhibiting a decrease in stress or anxiety-related behaviours during stressful events. This is a significant finding for pet owners who struggle to comfort their pets during thunderstorms, fireworks, or separation anxiety.
Kindred's comprehensive approach includes not only premium products but also an innovative clinical education platform for veterinarians. This platform* provides vets with access to the latest research, educational resources, and evidence-based guidance, empowering them to confidently integrate medicinal cannabis into their practice.
Quality and safety are at the forefront of Kindred's operations. All products undergo stringent quality control measures, including independent testing and strict compounding protocols, to ensure that pets receive consistent and reliable treatments.
Adam Guskich, Founder & CEO of Medigrowth*, emphasised the company's commitment to improving pet health outcomes and supporting veterinarians. 'We recognised that animals, like humans, can benefit significantly from medicinal cannabis,' said Guskich. 'Our mission is to improve pet health outcomes while empowering veterinarians with the knowledge and tools to incorporate these natural therapies into their practice.'
The launch of Kindred comes at a pivotal moment, as interest in plant-based medicine surges worldwide. With the plant-based medicine market projected to hit $127B by 2028*, Medigrowth is inviting Australians to invest in the future of pet healthcare. Expressions of Interest for Medigrowth’s crowdfunding campaign on Birchal opened on February 4, 2025, allowing investors to get in early on this fast-growing sector. Learn more here.*
Medigrowth has already secured key licenses from the Australian Federal Office of Drug Control and established major supply and distribution agreements, ensuring its place in the growing plant-based medicine market
In a show of support for animal welfare, Kindred has pledged to donate one dollar from every prescription processed to the RSPCA*, aiding animal protection services across Australia. This initiative reflects the company's broader mission to make a positive impact that extends beyond its commercial operations.
Who is Medigrowth?
Medigrowth Australia* distributes pharmaceutical grade, Australian-produced AU Good Manufacturing Practice (GMP) medicinal cannabis oils and locally grown dried cannabis flower. Australian-owned and operated, Medigrowth is fully licensed by the Federal Office of Drug Control for medicinal cannabis cultivation, manufacturing and research.
The launch of Kindred is a significant milestone for Australian veterinary care, offering vets and pet owners access to cutting-edge medicinal cannabis products backed by solid research and clinical expertise.
There is also the rare opportunity to invest in the future of plant medicine for pets through Medigrowth's crowdfunding campaign. If you’re interested in investing, you can read more here.*
I know I’ll be keeping a close eye on this one as the owner of an anxiety-medicated dog. It’s great to see huge strides in pet care, to not just provide relief but to give our furry companions the best care, and life, possible.
Whether you're a pet owner curious about CBD’s benefits or an investor looking for a high-growth opportunity, Kindred by Medigrowth is worth exploring. Expressions of Interest for Medigrowth’s crowdfunding campaign are now open on Birchal—find out more here*.
Members, would you be open to the use of medicinal cannabis for your pets? I’d love to hear from you.
*Please note, members, that this is a sponsored article. All content with an asterisk next to it means we may get a commission when you click on a link—at no cost to you! We do this to assist with the costs of running the SDC. Thank you!
This caught our attention not just because of the opportunities it presents for pet owners but also from an investment perspective—more on that shortly.
Pets are more than just animals; they're beloved companions that bring joy, comfort, and a sense of purpose. As our pets age alongside us, they, too, face health challenges, from anxiety to chronic pain and arthritis. It's heart-wrenching to see them in discomfort, and traditional treatments can sometimes fall short. That's where Kindred steps in*, offering a new hope for pet health and wellness.
For happier, healthier pets. Image Credit: Kindred
Kindred's mission is rooted in the belief that pets deserve the same level of care and attention as their human counterparts. Leveraging the success of Medigrowth's human medicinal cannabis products, Kindred is introducing a comprehensive range of veterinary products, including high-quality supplements and prescription-based medicinal cannabis treatments* for a tailored approach to address various pet health issues.
Recent CBD medication trials in dogs have shown promising results, with 83% of participating canines exhibiting a decrease in stress or anxiety-related behaviours during stressful events. This is a significant finding for pet owners who struggle to comfort their pets during thunderstorms, fireworks, or separation anxiety.
Kindred's comprehensive approach includes not only premium products but also an innovative clinical education platform for veterinarians. This platform* provides vets with access to the latest research, educational resources, and evidence-based guidance, empowering them to confidently integrate medicinal cannabis into their practice.
Quality and safety are at the forefront of Kindred's operations. All products undergo stringent quality control measures, including independent testing and strict compounding protocols, to ensure that pets receive consistent and reliable treatments.
Adam Guskich, Founder & CEO of Medigrowth*, emphasised the company's commitment to improving pet health outcomes and supporting veterinarians. 'We recognised that animals, like humans, can benefit significantly from medicinal cannabis,' said Guskich. 'Our mission is to improve pet health outcomes while empowering veterinarians with the knowledge and tools to incorporate these natural therapies into their practice.'
The launch of Kindred comes at a pivotal moment, as interest in plant-based medicine surges worldwide. With the plant-based medicine market projected to hit $127B by 2028*, Medigrowth is inviting Australians to invest in the future of pet healthcare. Expressions of Interest for Medigrowth’s crowdfunding campaign on Birchal opened on February 4, 2025, allowing investors to get in early on this fast-growing sector. Learn more here.*
Medigrowth has already secured key licenses from the Australian Federal Office of Drug Control and established major supply and distribution agreements, ensuring its place in the growing plant-based medicine market
Kindred has pledged to donate one dollar from every prescription processed to the RSPCA. Image Credit: Kindred
In a show of support for animal welfare, Kindred has pledged to donate one dollar from every prescription processed to the RSPCA*, aiding animal protection services across Australia. This initiative reflects the company's broader mission to make a positive impact that extends beyond its commercial operations.
Who is Medigrowth?
Medigrowth Australia* distributes pharmaceutical grade, Australian-produced AU Good Manufacturing Practice (GMP) medicinal cannabis oils and locally grown dried cannabis flower. Australian-owned and operated, Medigrowth is fully licensed by the Federal Office of Drug Control for medicinal cannabis cultivation, manufacturing and research.
The launch of Kindred is a significant milestone for Australian veterinary care, offering vets and pet owners access to cutting-edge medicinal cannabis products backed by solid research and clinical expertise.
There is also the rare opportunity to invest in the future of plant medicine for pets through Medigrowth's crowdfunding campaign. If you’re interested in investing, you can read more here.*
I know I’ll be keeping a close eye on this one as the owner of an anxiety-medicated dog. It’s great to see huge strides in pet care, to not just provide relief but to give our furry companions the best care, and life, possible.
Whether you're a pet owner curious about CBD’s benefits or an investor looking for a high-growth opportunity, Kindred by Medigrowth is worth exploring. Expressions of Interest for Medigrowth’s crowdfunding campaign are now open on Birchal—find out more here*.
Members, would you be open to the use of medicinal cannabis for your pets? I’d love to hear from you.
*Please note, members, that this is a sponsored article. All content with an asterisk next to it means we may get a commission when you click on a link—at no cost to you! We do this to assist with the costs of running the SDC. Thank you!
